Wednesday, October 24, 2018 The CCTG SRC.6 (COG ARST1321) study is now closed to accrual. Thanks to the hard work of many across the CCTG group and collaborative working processes with our pediatric colleagues the SRC.6 trial met its primary endpoint early. Addition of pazopanib to preoperative chemoradiation increased rates of complete pathological response for individuals with sarcoma. Additional follow up is planned to determine if this translates into improved event free and overall survival. A huge thank you to everybody who contributed to this success. SRC.6 trial - Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib. Determine feasibility of pazopanib + radiation or chemoradiation (phase II. Compare rates of complete pathologic response in patients receiving radiation or chemoradiation +/- pazopanib (phase II).Compare rates of EFS in patients receiving radiation +/- pazopanib (phase III) Secondary: Estimate and compare rates of local, regional and distant failure, DFS and OS. Compare patterns of recurrence. Define toxicities of pazopanib in combination with radiation or chemoradiation. The study was temporarily closed to accrual on October 1, 2018 for an interim analysis. Results from this analysis were reviewed by the COG Data Safety and Monitoring Committee (DSMC). The DSMC recommended that enrollment to the study be stopped and trial results be made public. Patients will continue on protocol therapy. Follow-up and data submission should continue according to the protocol.
